Printer Friendly

THE LIPOSOME COMPANY AND MERCK EXTEND AIDS RESEARCH AGREEMENT

 THE LIPOSOME COMPANY AND MERCK EXTEND AIDS RESEARCH AGREEMENT
 PRINCETON, N.J., July 14 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) and Merck & Co., Inc. (NYSE: MRK) have signed an extension of an agreement between the two companies to formulate and test an antigen associated with the Liposome Company's proprietary adjuvant, TLC A-60, to be used against the HIV virus. The antigen is a proprietary peptide developed by Merck in collaboration with Repligen Corporation. The companies' action today is an extension of an agreement signed in August of last year and is based on results seen so far.
 In January of this year, the Liposome Company and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP), signed an agreement for the development of a human influenza vaccine incorporating the TLC A-60 adjuvant. Work on that vaccine is continuing.
 "It is becoming increasingly clear that our unique TLC A-60 adjuvant system may have application in a wide variety of vaccines," said Charles A. Baker, chairman and chief executive officer of the Liposome Company. "We will continue to seek to maximize the value of this vaccine technology through agreements with leading pharmaceutical companies."
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of life-threatening illnesses.
 -0- 7/14/92
 /CONTACT: Anne M. Van Lent, senior vice president of the Liposome Company, Inc., 609-452-7060/
 (LIPO MRK) CO: Liposome Company, Inc.; Merck & Co., Inc. ST: New Jersey IN: MTC SU:


PS-LD -- NY005 -- 8952 07/14/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:264
Previous Article:COMMON FUND NAMES DAVID STORRS TO SUCCEED GEORGE KEANE AS PRESIDENT
Next Article:ARDEN INTERNATIONAL KITCHENS ANNOUNCES MANAGEMENT AGREEMENT
Topics:


Related Articles
3M AND THE LIPOSOME COMPANY ANNOUNCE OPTION AGREEMENT
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
FORMER MERCK EXECUTIVE APPOINTED TO LIPOSOME COMPANY BOARD OF DIRECTORS
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF ETHMOZINE FROM DU PONT MERCK
THE DU PONT MERCK PHARMACEUTICAL COMPANY AND BRITISH TECHNOLOGY GROUP USA SIGN AGREEMENT TO TRANSFER PHARMACEUTICAL TECHNOLOGIES
DU PONT MERCK WILL CO-PROMOTE NEW WELLCOME EPILEPSY DRUG
DUPONT MERCK PHARMA FACILITY IN MANATI TO MANUFACTURE PRODUCTS FOR ARES-SERONO
MITOTIX AND THE DUPONT MERCK PHARMACEUTICAL COMPANY SIGN AGREEMENT TO DEVELOP CELL CYCLE-BASED DRUGS TO TREAT CANCER
Stadtlanders Pharmacy and DuPont Merck Announce Joint Development Agreement; Advanced Program to Enhance Quality of Care for Parkinson's Patients
Wyeth-Ayerst to Market Abelcet(R) in Greece For The Liposome Company

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters